Quadrant Capital Group’s Arbutus Biopharma ABUS Stock Holding History

Quadrant Capital Group’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.25K	Hold	277	–	–	﹤0.01%	2560
2025 Q4	$1.33K	Hold	277	–	–	﹤0.01%	2569
2025 Q3	$1.26K	Buy	+277	New	+$1.02K	﹤0.01%	2538
2025 Q2	–	Sell	-878	Closed	-$3.06K	–	1343
2025 Q1	$3.06K	Hold	878	–	–	﹤0.01%	2447
2024 Q4	$2.87K	Hold	878	–	–	﹤0.01%	2445
2024 Q3	$3.38K	Hold	878	–	–	﹤0.01%	2398
2024 Q2	$2.71K	Hold	878	–	–	﹤0.01%	2426
2024 Q1	$2.27K	Buy	878 +601	+217%	+$1.56K	﹤0.01%	2483
2023 Q4	$693	Sell	277 -635	-70%	-$1.24K	﹤0.01%	2587
2023 Q3	$1.85K	Buy	+912	New	+$1.91K	﹤0.01%	2411
2023 Q2	–	Sell	-205	Closed	-$622	–	2683
2023 Q1	$622	Hold	205	–	–	﹤0.01%	2579
2022 Q4	$478	Sell	205 -5,196	-96%	-$12.4K	﹤0.01%	2626
2022 Q3	$10K	Buy	+5,401	New	+$12.7K	﹤0.01%	1875

Other funds holding ABUS

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

WCM

Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Quadrant Capital Group's ABUS Position: Q1 2026 in Review

Quadrant Capital Group held its Arbutus Biopharma (ABUS) position steady in Q1 2026 at 277 shares worth $1.25K. The position accounts for ﹤0.01% of the portfolio, ranked #2560.

Quadrant Capital Group first reported a position in ABUS in Q3 2022 and has held it in 13 quarters since. The position peaked at $10K in Q3 2022. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

Quadrant Capital Group held 277 shares of Arbutus Biopharma worth $1.25K as of Q1 2026.
Quadrant Capital Group left its Arbutus Biopharma share count unchanged in Q1 2026.
Arbutus Biopharma made up ﹤0.01% of Quadrant Capital Group's portfolio in Q1 2026, its #2560 holding.
Quadrant Capital Group first reported a position in Arbutus Biopharma in Q3 2022 and has held it in 13 quarters since.
Quadrant Capital Group's Arbutus Biopharma position peaked at $10K in Q3 2022.
167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.